Abstract
Acute lymphoblastic leukaemia (ALL) is the most common malignant disease of childhood, but can also occur in adults. Whilst long-term survival rates in childhood ALL have steadily improved over the past 50 years, adults with ALL fare much more poorly, a problem due in part to the lack of large-scale randomised trials in treating adult ALL. The largest ever study to look specifically at adult ALL is the International ALL trial, initiated in 1993, and its results have recently been published, addressing in particular the role of stem cell transplantation in ALL treatment. The trial (known as UKALL XII in the UK) confirms the efficacy of current chemotherapy in inducing disease remission. It addresses the issue of whether patients with the Philadelphia chromosome should receive allogeneic stem cell transplants, reporting that this gives a small but significant improvement in outcome, and challenges the current view that in Philadelphia-negative ALL, patients deemed to be ‘higher-risk’ benefit more from transplantation. Autologous stem cell transplantation, previously thought to prolong survival in adult ALL, is shown to be worse than conventional chemotherapy. The UKALL XII data have not yet been published for imatinib, a BCR-ABL fusion protein inhibitor useful in Philadelphia-positive disease, but will undoubtedly add to a growing body of knowledge with the potential to improve outcomes in this often overlooked form of cancer.